MIRA
INFORM REPORT
|
Report Date : |
21.02.2008 |
IDENTIFICATION
DETAILS
|
Name : |
RASCO PHARMA |
|
|
|
|
Registered Office : |
Plot
No. 27, Holiday Park Industrial
Estate, 5.5 KM. Raiwind Road, Lahore |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Date of Incorporation : |
2004 |
|
|
|
|
Legal Form : |
Partnership business |
|
|
|
|
Line of Business : |
Manufacture & Marketing of Pharmaceutical Products |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Small Company |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
Business Name
RASCO PHARMA
Full Address
Registered Address & Factory
Plot No. 27, Holiday Park Industrial Estate, 5.5 KM. Raiwind Road,
Lahore, Pakistan
Tel 92 (42) 5321715, 5321716, 5324078
Fax 92 (42) 5321346,
5324079
Short Description Of Business
|
Nature of Business |
Manufacture & Marketing of Pharmaceutical Products |
|
Year Established |
2004 |
|
National Tax # |
1511794 |
Branches
In Rawalpindi & Karachi
Legal Status
Subject Company was established as a Partnership business in 2004
Details of Management
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Mohammad Rashid Sajjad Mrs. Rashid Sajjad |
Pakistani Pakistani |
Plot No. 27, Holiday Park Industrial Estate, 5.5 KM. Raiwind
Road, Lahore Plot No. 27, Holiday Park Industrial Estate, 5.5 KM. Raiwind
Road, Lahore |
Business Business |
Managing Partner Partner |
Associates
Subsidiary
None
Associated companies
-Do-
Products
(1) Subject Company is engaged in manufacture & marketing of Pharmaceutical Products.
(2) It purchases raw material against D/A, L/C basis.
(3) Its’ major customers are Distributors, Traders, Pharmacies & Hospitals located in Peshawar, Quetta & Lahore.
(4) Subject operates from caption leased factory premises of area measuring 2,000 Sq.Yard. which is situated in industrial area.
(5) Subject employs about 90 persons in its set up.
Products
A-ROX, AEROTEC, ANAC,
B-LEX, BRIMDIN, CEF-EURO, COLSTAT, CONSILAC, DIZET, ENOXA, FEXATIN, GEOX,
GROBIN-F, LEVOFLOXA, LOMECIN, LORTEC, MULTEX, NIL-GESIC, NILCLOT, OFENAD,
OLANZIN, PELACIN, PHENOTONE, POLYHEAM, PRISMA, RACIP, RASBID, RASCODOL,
RASCOTRAN, RASDIPIN, RASMIC, RASMIC FORTE, RASTHRO, REFSPAN, REL-XICAM,
RELOSEF, RELSEC, RESCAMET, RESCARD, RESCOMYCIN, RESCOTIL, RESDRYL, RESFEN,
RESGYL, RESIDONE, RESINAC, RESINAC FORTE, RESMIN, RESOTAC, RESPAR, ROZEN,
THERACID, VASCAM, VIMTIN, VULAMOX
Trade Suppliers
ZHEJIANG CHEMICAL IMPORT & EXPORT CORP, CHINA.
VITAL-CHEM ZHUHAI CO. LTD, CHINA.
SINOCHEM SHANGHAI CORPORATION, CHINA.
Annual Sales Volume
|
Year |
In Pak Rupees
|
|
2006 - 2007 |
40,000,000/- (Estimated) |
Capacity & Production
The capacity and production of the company’s plant is indeterminable as it is multi- product and involves various processes of manufacture.
Authorized Distributors
Mainly in major cities including Peshawar, Quetta & Lahore
Bankers
Bank Alhabib Limited, Pakistan.
The Bank of Punjab, Pakistan.
Standard Chartered Bank, Pakistan.
Memberships
Pakistan Pharmaceutical Manufacturers Association.(PPMA)
Foreign Exchange Rates
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 63.00 |
|
UK Pound |
1 |
Rs. 120.00 |
|
Euro |
1 |
Rs.
90.60 |
Comments
Subject Company was established in 2004 and
is engaged in manufacture & marketing of Pharmaceutical Products. Trade
relations are reported as fair. Company can be considered for normal business dealings
at usual trade terms and conditions.
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)